Compare NGS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | BBNX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 558.5M | 493.1M |
| IPO Year | 2006 | N/A |
| Metric | NGS | BBNX |
|---|---|---|
| Price | $38.98 | $16.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $40.67 | $23.80 |
| AVG Volume (30 Days) | 124.2K | ★ 1.1M |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 14.60 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $172,315,000.00 | N/A |
| Revenue This Year | $15.05 | $34.90 |
| Revenue Next Year | $9.52 | $34.63 |
| P/E Ratio | $74.45 | ★ N/A |
| Revenue Growth | ★ 9.94 | N/A |
| 52 Week Low | $22.72 | $8.80 |
| 52 Week High | $44.61 | $32.71 |
| Indicator | NGS | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 67.27 |
| Support Level | $38.57 | $16.02 |
| Resistance Level | $40.34 | $32.52 |
| Average True Range (ATR) | 1.78 | 1.07 |
| MACD | -0.29 | 0.16 |
| Stochastic Oscillator | 10.91 | 89.90 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.